GlaxoSmithKline CFO Interviewed on Q2 Results

LONDON, July 24, 2013 /PRNewswire/ --

Simon Dingemans, CFO, outlines the UK pharma group's Q2 performance, positive R&D pipeline news, as well as outlook and guidance for the rest of the year. 

Dingemans also gives an update on his financial strategy plan, saying, "you could see in the second quarter the benefits of the restructuring programmes and some of the financial efficiencies we've identified really contributing to drive that leverage through the P&L and accelerate earnings per share of 4% faster than the sales growth of two per cent."

The video interviews and transcripts are available now on http://video.merchantcantos.com.

MerchantCantos produces in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email [email protected] or phone +44-(0)207-936-1352.

SOURCE GlaxoSmithKline

Suggested Articles

IBM and Pfizer developed an artificial intelligence model that could eventually predict if a person will develop Alzheimer’s using a language test.

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.